Albumin and Crystalloid Administration in Septic Shock

Launched by ASAN MEDICAL CENTER · Nov 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the early administration of a protein called albumin, along with regular fluids, affects the survival of patients suffering from septic shock. Septic shock is a serious condition that occurs when an infection leads to dangerously low blood pressure and inadequate blood flow to the organs. The researchers want to find out if giving albumin as part of the initial treatment helps patients recover better compared to those who only receive regular fluids without albumin.

To participate in this trial, individuals must be adults (18 years or older) who arrive at the emergency department and are suspected of having septic shock. Key signs of septic shock include very low blood pressure and high levels of lactic acid in the blood. However, certain patients, such as those who have already received albumin or have serious health issues that limit their treatment options, will not be eligible. Participants can expect to receive standard care in the emergency department, and their progress will be closely monitored to gather important information about their recovery. This trial is currently recruiting participants of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥ 18 years) who visit an ED directly and are suspected of sepsis with shock
• • Shock is defined as hypotension (mean arterial blood pressure (MAP) \< 65 or systolic blood pressure \< 80) and tissue hypoperfusion such as an initial serum lactate level ≥ 4 mmol/dL.
• Exclusion Criteria:
• • patients who are transferred from another hospital after initial fluid administration
• • patients who have set limitations on treatment (e.g. patients with a signed do-not-resuscitate order)
• • patients with moribund conditions with life expectancy less than 28 days due to secondary diseases or advanced malignant disease and palliative situations with life expectancy less than 6 months
• • patients who have been administered albumin before enrollment
• • patients who have known hypersensitivity to albumin
• • Clinical conditions, where albumin administration may be unfavorable (e.g. pulmonary edema, congestive heart failure, traumatic brain injury)
• • lactation
• • patients who do not voluntarily consent to participate in the trial.